{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:28:00Z","timestamp":1790015280026,"version":"4.0.1"},"reference-count":158,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute (NEI) of the National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY031452"],"award-info":[{"award-number":["R01EY031452"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Recent advances in molecular biology have led to the development of RNA-based therapeutics, offering significant promise for treating various eye diseases. Current RNA therapeutics include RNA aptamers, antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA) that can target specific genetic and molecular pathways involved in eye disorders. In addition to their potential in therapy, RNA technologies have also provided tools for mechanistic studies to improve the understanding of eye diseases, expanding the possibilities of RNA-based treatments. Despite the utility of RNA in studying eye disease mechanisms and its potential in disease treatment, only a few RNA-based therapies have been approved for posterior eye diseases. This paper reviews RNA interference and related ocular delivery and posterior eye diseases, focusing on the use of RNA aptamers, siRNA, short hairpin RNA (shRNA), and microRNA (miRNA). Approaches using RNA to advance our understanding of eye diseases and disease treatments, particularly in the posterior segment of the eye, are discussed. It is concluded that RNA therapeutics offer a novel approach to treating a variety of eye diseases by targeting their molecular causes. siRNA, shRNA, miRNA, and ASO can directly silence disease-driving genes, while RNA aptamers bind to specific targets. Although many RNA-based therapies are still in experimental stages, they hold promise for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), glaucoma, and inherited retinal disorders. Effective delivery methods and long-term safety are key challenges that need to be addressed for these treatments to become widely available.<\/jats:p>","DOI":"10.3390\/pharmaceutics17101326","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:13:27Z","timestamp":1760361207000},"page":"1326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies"],"prefix":"10.3390","volume":"17","author":[{"given":"Mohammed S. Abdel-Raziq","family":"Hassan","sequence":"first","affiliation":[{"name":"Department of Chemistry, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8626-9630","authenticated-orcid":false,"given":"S. Kevin","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"ref_1","first-page":"CD009300","article-title":"Complement inhibitors for age-related macular degeneration","volume":"2014","author":"Williams","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.2174\/092986711797189600","article-title":"Nucleic acid aptamers: Clinical applications and promising new horizons","volume":"18","author":"Ni","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108482","DOI":"10.1016\/j.exer.2021.108482","article-title":"RNA therapeutics in ophthalmology\u2014Translation to clinical trials","volume":"205","author":"Gupta","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/15476286.2022.2027150","article-title":"Innovative developments and emerging technologies in RNA therapeutics","volume":"19","author":"Halloy","year":"2022","journal-title":"RNA Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","article-title":"RNA editing: Expanding the potential of RNA therapeutics","volume":"31","author":"Booth","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.drudis.2014.02.009","article-title":"Aptamer-based therapeutics of the past, present and future: From the perspective of eye-related diseases","volume":"19","author":"Kanwar","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: Beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/01.RES.83.3.233","article-title":"Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization","volume":"83","author":"Asahara","year":"1998","journal-title":"Circ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.0831159100","article-title":"Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2","volume":"100","author":"White","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Akwii, R.G., Sajib, M.S., Zahra, F.T., and Mikelis, C.M. (2019). Role of Angiopoietin-2 in vascular physiology and pathophysiology. Cells, 8.","DOI":"10.3390\/cells8050471"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1080\/15384101.2016.1196303","article-title":"Suppression of KSHV-induced angiopoietin-2 inhibits angiogenesis, infiltration of inflammatory cells, and tumor growth","volume":"15","author":"Yu","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: First approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425247.3.2.275","article-title":"Ocular drug delivery","volume":"3","author":"Ghate","year":"2006","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000209665","article-title":"Novel drug delivery systems for retinal diseases: A review","volume":"41","author":"Lee","year":"2009","journal-title":"Ophthalmic Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jop.2017.0121","article-title":"Intravitreal, subretinal, and suprachoroidal injections: Evolution of microneedles for drug delivery","volume":"34","author":"Hartman","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.nano.2009.02.003","article-title":"Nanomedicines for ocular NSAIDs: Safety on drug delivery","volume":"5","author":"Araujo","year":"2009","journal-title":"Nanomedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0169-409X(95)00017-2","article-title":"Microspheres and nanoparticles used in ocular delivery systems","volume":"16","author":"Zimmer","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drudis.2007.11.002","article-title":"Current and future ophthalmic drug delivery systems. A shift to the posterior segment","volume":"13","author":"Urtti","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2147\/OPTH.S12846","article-title":"A protocol for the retina surgeon\u2019s safe initial intravitreal injections","volume":"4","author":"Frenkel","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_25","first-page":"S15","article-title":"Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir","volume":"88","author":"Ausayakhun","year":"2005","journal-title":"J. Med. Assoc. Thai"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: An overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","article-title":"RNA-based therapeutics: Current progress and future prospects","volume":"19","author":"Burnett","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"114342","DOI":"10.1016\/j.addr.2022.114342","article-title":"Polymer based sustained drug delivery to the ocular posterior segment: Barriers and future opportunities for the treatment of neovascular pathologies","volume":"187","author":"Alshaikh","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1389450053765914","article-title":"Colloidal carriers for ophthalmic drug delivery","volume":"6","author":"Mainardes","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"ref_32","first-page":"513","article-title":"Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation","volume":"68","author":"Motwani","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1002\/jps.22137","article-title":"A nonionic surfactant\/chitosan micelle system in an innovative eye drop formulation","volume":"99","author":"Pepic","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/jop.2007.0002","article-title":"Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model","volume":"23","author":"Xu","year":"2007","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.biopha.2018.08.092","article-title":"Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy","volume":"107","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10717544.2010.483257","article-title":"Solid lipid nanoparticles for ocular drug delivery","volume":"17","author":"Seyfoddin","year":"2010","journal-title":"Drug Deliv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02713681003760168","article-title":"Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs","volume":"35","author":"Souto","year":"2010","journal-title":"Curr. Eye Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2010.06.006","article-title":"Polymeric micelle gene delivery of bcl-xL via eye drop reduced corneal apoptosis following epithelial debridement","volume":"147","author":"Tong","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2012.01.019","article-title":"Liposomes for intravitreal drug delivery: A state of the art","volume":"161","author":"Bochot","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/jop.2008.0031","article-title":"Development of effective ocular preparations of antifungal agents","volume":"24","author":"Kaur","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2010.11.030","article-title":"The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/med.21509","article-title":"Gold nanoparticles in ophthalmology","volume":"39","author":"Masse","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s11671-023-03943-0","article-title":"Exploration of inorganic nanoparticles for revolutionary drug delivery applications: A critical review","volume":"18","author":"Unnikrishnan","year":"2023","journal-title":"Discov. Nano"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114899","DOI":"10.1016\/j.addr.2023.114899","article-title":"Advances in development of exosomes for ophthalmic therapeutics","volume":"199","author":"Tian","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s11095-013-1226-x","article-title":"Ocular delivery of pRNA nanoparticles: Distribution and clearance after subconjunctival injection","volume":"31","author":"Feng","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"124151","DOI":"10.1016\/j.ijpharm.2024.124151","article-title":"Posterior eye delivery of angiogenesis-inhibiting RNA nanoparticles via subconjunctival injection","volume":"657","author":"Zhong","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.addr.2006.07.020","article-title":"Ocular delivery of nucleic acids: Antisense oligonucleotides, aptamers and siRNA","volume":"58","author":"Fattal","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.tibtech.2024.05.002","article-title":"Ocular RNA nanomedicine: Engineered delivery nanoplatforms in treating eye diseases","volume":"42","author":"Zhang","year":"2024","journal-title":"Trends Biotechnol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: Delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"115116","DOI":"10.1016\/j.addr.2023.115116","article-title":"Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery","volume":"203","author":"Saiding","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.nano.2020.102181","article-title":"Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: Formulation and in vivo efficacy evaluation","volume":"26","author":"Chaharband","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Alanazi, J.S., Alqahtani, F.Y., Aleanizy, F.S., Radwan, A.A., Bari, A., Alqahtani, Q.H., Abdelhady, H.G., and Alsarra, I. (2022). MicroRNA-539-5p-loaded PLGA nanoparticles grafted with iRGD as a targeting treatment for choroidal neovascularization. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020243"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.actbio.2021.07.053","article-title":"A core-shell nanoplatform as a nonviral vector for targeted delivery of genes to the retina","volume":"134","author":"Tan","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103553","DOI":"10.1016\/j.jddst.2022.103553","article-title":"Lipid nanoparticles in the development of mRNA vaccines for COVID-19","volume":"74","author":"Wilson","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2013From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2011.11.022","article-title":"Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: An in-vivo study in rats and mice","volume":"160","author":"Hagigit","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_59","first-page":"1029","article-title":"Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells","volume":"19","author":"Mitra","year":"2013","journal-title":"Mol. Vis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.06.030","article-title":"In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles","volume":"336","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2020.04.052","article-title":"A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries","volume":"324","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eabj9617","DOI":"10.1126\/sciadv.abj9617","article-title":"miR-204-containing exosomes ameliorate GVHD-associated dry eye disease","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-023-00260-y","article-title":"Accelerating corneal wound healing using exosome-mediated targeting of NF-\u03baB c-Rel","volume":"43","author":"Zhao","year":"2023","journal-title":"Inflamm. Regen."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41551-021-00764-3","article-title":"Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells","volume":"5","author":"Tian","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41551-023-01112-3","article-title":"Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases","volume":"8","author":"Bao","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: A randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: Results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1021\/bi4017022","article-title":"Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments","volume":"53","author":"Binzel","year":"2014","journal-title":"Biochemistry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1021\/acs.chemrev.1c00009","article-title":"Thermostability, tunability, and tenacity of RNA as rubbery anionic polymeric materials in nanotechnology and nanomedicine-specific cancer targeting with undetectable toxicity","volume":"121","author":"Binzel","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.addr.2013.11.006","article-title":"Stable RNA nanoparticles as potential new generation drugs for cancer therapy","volume":"66","author":"Shu","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2017.11.028","article-title":"RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels","volume":"270","author":"Shi","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7920631","DOI":"10.1155\/2016\/7920631","article-title":"Small interfering RNA targeted to ASPP2 promotes progression of experimental proliferative vitreoretinopathy","volume":"2016","author":"Chen","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00395-014-0404-2","article-title":"Brag2 differentially regulates \u03b21- and \u03b23-integrin-dependent adhesion in endothelial cells and is involved in developmental and pathological angiogenesis","volume":"109","author":"Manavski","year":"2014","journal-title":"Basic Res. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1167\/iovs.08-2954","article-title":"Anti-inflammatory and antioxidant effects of SERPINA3K in the retina","volume":"50","author":"Zhang","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"109753","DOI":"10.1016\/j.exer.2023.109753","article-title":"Aurora kinase B disruption suppresses pathological retinal angiogenesis by affecting cell cycle progression","volume":"239","author":"Zhu","year":"2024","journal-title":"Exp. Eye Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ceca.2015.01.002","article-title":"Suppression of transient receptor potential canonical channel 4 inhibits vascular endothelial growth factor-induced retinal neovascularization","volume":"57","author":"Song","year":"2015","journal-title":"Cell Calcium"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3760\/cma.j.issn.0366-6999.20130199","article-title":"Small interference RNA targeting vascular endothelial growth factor gene effectively attenuates retinal neovascularization in mice model","volume":"126","author":"Kong","year":"2013","journal-title":"Chin. Med. J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Dong, X., Wang, Y.S., Dou, G.R., Hou, H.Y., Shi, Y.Y., Zhang, R., Ma, K., Wu, L., Yao, L.B., and Cai, Y. (2011). Influence of Dll4 via HIF-1\u03b1-VEGF signaling on the angiogenesis of choroidal neovascularization under hypoxic conditions. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018481"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1167\/iovs.09-3457","article-title":"Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo","volume":"51","author":"Hirano","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.mvr.2017.03.003","article-title":"The role of FoxO1 in interleukin-1beta-induced autostimulation in retina endothelial cells and retinas of diabetic rats","volume":"112","author":"Wu","year":"2017","journal-title":"Microvasc. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1111\/j.1442-9071.2011.02656.x","article-title":"Caveolin-1 expression regulates blood-retinal barrier permeability and retinal neovascularization in oxygen-induced retinopathy","volume":"40","author":"Tian","year":"2012","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: Biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.molcel.2014.10.025","article-title":"A computational algorithm to predict shRNA potency","volume":"56","author":"Knott","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1096\/fj.201700640R","article-title":"miR-539-5p inhibits experimental choroidal neovascularization by targeting CXCR7","volume":"32","author":"Feng","year":"2018","journal-title":"FASEB J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exer.2018.06.010","article-title":"MicroRNA-188-5p regulates contribution of bone marrow-derived cells to choroidal neovascularization development by targeting MMP-2\/13","volume":"175","author":"Hou","year":"2018","journal-title":"Exp. Eye Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00125-014-3197-9","article-title":"miR-195 regulates SIRT1-mediated changes in diabetic retinopathy","volume":"57","author":"Mortuza","year":"2014","journal-title":"Diabetologia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00125-015-3832-0","article-title":"miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway","volume":"59","author":"Zhao","year":"2016","journal-title":"Diabetologia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2337\/db11-0478","article-title":"miR-146a-mediated extracellular matrix protein production in chronic diabetes complications","volume":"60","author":"Feng","year":"2011","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, Y., Wang, X., Ma, Y., Li, Z., and Di, Y. (2022). LncRNA TUG1 promotes apoptosis, invasion, and angiogenesis of retinal endothelial cells in retinopathy of prematurity via MiR-145-5p. Front. Med., 9.","DOI":"10.3389\/fmed.2022.803214"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"103568","DOI":"10.18632\/oncotarget.21592","article-title":"STAT3-mediated activation of miR-21 is involved in down-regulation of TIMP3 and neovascularization in the ischemic retina","volume":"8","author":"Gutsaeva","year":"2017","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exer.2012.02.013","article-title":"Aquaporin 4 knockdown exacerbates streptozotocin-induced diabetic retinopathy through aggravating inflammatory response","volume":"98","author":"Cui","year":"2012","journal-title":"Exp. Eye Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2011.03.005","article-title":"Inhibition of hypoxia-induced retinal neovascularization in mice with short hairpin RNA targeting Rac1, possibly via blockading redox signaling","volume":"92","author":"Zhang","year":"2011","journal-title":"Exp. Eye Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"147212","DOI":"10.1016\/j.gene.2023.147212","article-title":"MicroRNA-21: A critical underestimated molecule in diabetic retinopathy","volume":"859","author":"Oladghaffari","year":"2023","journal-title":"Gene"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the treatment of wet, age-related macular degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol. Eye Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.gt.3302641","article-title":"Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1","volume":"13","author":"Shen","year":"2006","journal-title":"Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1167\/iovs.12-9961","article-title":"Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study)","volume":"53","author":"Nguyen","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.ophtha.2012.03.043","article-title":"Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Pfeiffer, N., Voykov, B., Renieri, G., Bell, K., Richter, P., Weigel, M., Thieme, H., Wilhelm, B., Lorenz, K., and Feindor, M. (2017). First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-\u03b22), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188899"},{"key":"ref_101","first-page":"1965","article-title":"Inhibition of retinal neovascularization by siRNA targeting VEGF(165)","volume":"14","author":"Xia","year":"2008","journal-title":"Mol. Vis."},{"key":"ref_102","first-page":"1563","article-title":"The inhibitory effect of small interference RNA protein kinase C-alpha on the experimental proliferative vitreoretinopathy induced by dispase in mice","volume":"8","author":"Gao","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00417-008-1023-0","article-title":"Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats","volume":"247","author":"Hou","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1167\/iovs.15-17511","article-title":"siRNA-mediated knockdown of the mTOR inhibitor RTP801 promotes retinal ganglion cell survival and axon elongation by direct and indirect mechanisms","volume":"57","author":"Spivak","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_105","first-page":"4575","article-title":"A Phase I open label, dose escalation trial of QPI-1007 delivered by a single intravitreal (IVT) injection to subjects with low visual acuity and acute non-arteritic anterior ischemic optic neuropathy (NAION)","volume":"54","author":"Antoszyk","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_106","unstructured":"AdisInsight (2025, September 19). QPI 1007. Available online: https:\/\/adisinsight.springer.com\/drugs\/800028983."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/mt.2013.217","article-title":"Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure","volume":"22","author":"Sadaba","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Turman","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_109","unstructured":"GER-GROUP (2025, September 19). AGN-745 (Sirna-027)\u2014Wet AMD Development Was Halted. Available online: https:\/\/amdbook.org\/content\/agn-745-sirna-027-wet-amd-development-was-halted."},{"key":"ref_110","unstructured":"ScienceDirect (2025, September 19). Sirna 027. Available online: https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/sirna-027."},{"key":"ref_111","unstructured":"AdisInsight (2025, September 19). PF4523655. Available online: https:\/\/adisinsight.springer.com\/drugs\/800025090."},{"key":"ref_112","unstructured":"Isarna-Therapeutics (2025, September 19). Looking Beyond the Standard of Care for Eye Diseases. Available online: https:\/\/www.nature.com\/articles\/d43747-021-00054-6."},{"key":"ref_113","unstructured":"Isarna-Therapeutics (2025, September 19). Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects with Glaucoma Undergoing Trabeculectomy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02406833."},{"key":"ref_114","first-page":"321","article-title":"Long-term safety and efficacy of ISTH0036\u2014A selective TGF-\u03b22 blocking antisense oligonucleotide in preclinical and Phase 1 clinical studies","volume":"62","author":"Ruckert","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_115","unstructured":"Quark-Pharmaceuticals (2025, September 19). Phase 2\/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02341560."},{"key":"ref_116","unstructured":"Sylentis (2025, September 19). SYL040012, Treatment for Open Angle Glaucoma (SYLTAG), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02250612."},{"key":"ref_117","unstructured":"Sylentis (2025, September 19). Tivanisiran. Available online: https:\/\/sylentis.com\/products-tivanisiran\/."},{"key":"ref_118","unstructured":"Sylentis (2025, September 19). Safety Study of Tivanisiran to Treat Dry Eye (FYDES), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05310422."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2016.06.020","article-title":"Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy","volume":"236","author":"Mitra","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/jop.2012.0077","article-title":"Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization","volume":"29","author":"Du","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_121","first-page":"1354","article-title":"Silencing of Rac1 expression via RNA interference inhibits retinal neovascularization in rats","volume":"18","author":"Li","year":"2012","journal-title":"Mol. Vis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/ijms15011606","article-title":"Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes","volume":"15","author":"Hu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E.N., Carter, J., Dalby, A.B., Eaton, B.E., and Fitzwater, T. (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015004"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1038\/mtna.2014.49","article-title":"Nucleic acid ligands with protein-like side chains: Modified aptamers and their use as diagnostic and therapeutic agents","volume":"3","author":"Rohloff","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_126","first-page":"CD009300","article-title":"Complement inhibitors for age-related macular degeneration","volume":"6","author":"Tzoumas","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Nakamura, Y. (2021). Multiple therapeutic applications of RBM-007, an anti-FGF2 aptamer. Cells, 10.","DOI":"10.3390\/cells10071617"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Iturriaga-Goyon, E., Vivanco-Rojas, O., Magana-Guerrero, F.S., Buentello-Volante, B., Castro-Salas, I., Aguayo-Flores, J.E., Gracia-Mora, I., Rivera-Huerta, M., Sanchez-Bartes, F., and Garfias, Y. (2021). AS1411 nucleolin-specific binding aptamers reduce pathological angiogenesis through inhibition of nucleolin phosphorylation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313150"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.exer.2015.09.005","article-title":"Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration","volume":"140","author":"Leaderer","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: A phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Adachi, H., Hengesbach, M., Yu, Y.T., and Morais, P. (2021). From antisense RNA to RNA modification: Therapeutic potential of RNA-based technologies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050550"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","article-title":"Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations","volume":"29","author":"Dulla","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.exer.2006.07.020","article-title":"Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: A key step in the progression of proliferative vitreoretinopathy","volume":"83","author":"Zhang","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_134","unstructured":"IVERIC-Bio (2025, September 19). Zimura in Participants with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02686658."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 Inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: A randomized pivotal Phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_136","unstructured":"Ribomic (2025, September 19). A Phase II Study of RBM-007 Alone and RBM-007 with Eylea\u00ae in Subjects with Wet Age-Related Macular Degeneration (TOFU), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04200248."},{"key":"ref_137","unstructured":"Ribomic (2025, September 19). Wet Age-Related Macular Degeneration (Wet AMD). Available online: https:\/\/www.ribomic.com\/eng\/pipeline\/rbm007.php."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","article-title":"Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: A Phase IIb, multicenter, randomized controlled trial","volume":"124","author":"Jaffe","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_139","unstructured":"Ophthotech_Corporation (2025, September 19). A Phase 3 Safety and Efficacy Study of Fovista\u00ae (E10030) Intravitreous Administration in Combination with Lucentis\u00ae Compared to Lucentis\u00ae Monotherapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01944839."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_142","unstructured":"ProQR-Therapeutics (2025, September 19). A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-Dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03913143."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1167\/iovs.15-16400","article-title":"Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration","volume":"56","author":"Murray","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_144","unstructured":"ProQR-Therapeutics (2025, September 19). A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects with Autosomal Dominant Retinitis Pigmentosa due to the P23H Mutation in the RHO Gene (AURORA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04123626."},{"key":"ref_145","first-page":"3250","article-title":"QR-421a, an antisense oligonucleotide, for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations","volume":"60","author":"Diepen","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_146","unstructured":"Laboratoires-Thea (2025, September 19). An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (HELIA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05085964."},{"key":"ref_147","unstructured":"ProQR-Therapeutics (2025, September 19). Study to Evaluate Safety and Tolerability of QR-421a in Subjects with RP due to Mutations in Exon 13 of the USH2A Gene (Stellar), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03780257."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"102394","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): A prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: A phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"ref_151","unstructured":"OPKO-Health (2025, September 19). Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00306904."},{"key":"ref_152","unstructured":"OPKO-Health (2025, September 19). Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00259753."},{"key":"ref_153","unstructured":"Allergan (2025, September 19). A Study Using Intravitreal Injections of a Small Interfering RNA in Patients with Age-Related Macular Degeneration, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00395057."},{"key":"ref_154","unstructured":"Quark-Pharmaceuticals (2025, September 19). PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With\/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT01445899."},{"key":"ref_155","unstructured":"Sylentis (2025, September 19). Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04782271."},{"key":"ref_156","unstructured":"HuidaGene-Therapeutics (2025, September 19). CRISPR\/cas13-mediated RNA Targeting Therapy for the Treatment of Neovascular Age-Related Macular Degeneration Investigator-Initiated Trial (SIGHT-I), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06031727."},{"key":"ref_157","unstructured":"HuidaGene-Therapeutics (2025, September 19). Open-Label Dose-Escalation Study for CRISPR\/cas13- RNA Targeting Therapy for the Treatment of Neovascular Age-Related Macular Degeneration in Phase I Trial (BRIGHT), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06623279."},{"key":"ref_158","unstructured":"Olix-Pharmaceuticals (2025, September 19). Evaluation of OLX10212 in Patients with Neovascular Age-Related Macular Degeneration, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05643118."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:23:48Z","timestamp":1760361828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":158,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pharmaceutics17101326"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17101326","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}